FDA Warns Public Again on Risk of Sterile Drugs From Compounder

Drug Industry Daily
A A
The FDA is warning healthcare providers and patients not to use sterile drugs made by an Oklahoma compounder after the firm refused to cease sterile operations following a failed inspection — the latest in a stream of safety alerts, warning letters and Form 483s having to do with compounders’ sterility practices over the past year.

To View This Article:

Login

Subscribe To Drug Industry Daily